Company profile for Actuate Therapeutics, Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Actuate was founded in 2015 with a mission of discovering, developing, and commercializing new agents that target GSK-3β, based on intellectual capital developed in the laboratories of Dr. Alan Kozikowski at the Univer...
Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Actuate was founded in 2015 with a mission of discovering, developing, and commercializing new agents that target GSK-3β, based on intellectual capital developed in the laboratories of Dr. Alan Kozikowski at the University of Illinois-Chicago and the Center for Developmental Therapeutics at Northwestern University.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1751 River Run, Suite 400 Fort Worth, TX 76107
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/22/3153932/0/en/Actuate-Therapeutics-Provides-FDA-with-Updated-Clinical-Data-Package-to-Support-Planned-Regulatory-Interactions-with-FDA-and-EMA-Over-the-Coming-Months.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/09/11/3148863/0/en/Actuate-Therapeutics-Announces-Closing-of-17-25-Million-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-Over-Allotment-Option.html

GLOBENEWSWIRE
11 Sep 2025

https://www.globenewswire.com/news-release/2025/09/10/3147761/0/en/Actuate-Therapeutics-Announces-Pricing-of-15-0-Million-Public-Offering-of-Common-Stock.html

GLOBENEWSWIRE
10 Sep 2025

https://www.globenewswire.com/news-release/2025/09/09/3147344/0/en/Actuate-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html

GLOBENEWSWIRE
09 Sep 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/actuate-therapeutics-advances-a-new-era-in-oncology-with-potential-universal-backbone-1064578

ACCESSWIRE
25 Aug 2025

https://www.globenewswire.com/news-release/2025/08/06/3128350/0/en/Actuate-Therapeutics-To-Collaborate-with-Incyte-Corporation-and-the-University-of-Pittsburgh-on-Clinical-Trial-of-Elraglusib-in-Combination-with-Retifanlimab-and-mFOLFIRINOX-in-Pat.html

GLOBENEWSWIRE
06 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty